EBF1 (E2I3Q) Rabbit mAb #57794
- WB
- IP
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 65 |
| Source/Isotype | IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:1600 - 1:3200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:1000 - 1:4000 |
Storage
Protocol
Specificity / Sensitivity
EBF1 (E2I3Q) Rabbit mAb recognizes endogenous levels of total EBF1 protein. This antibody may cross-react with EBF2 and EBF3.
Species Reactivity:
Human
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly500 of human EBF1 protein.
Background
Early B-cell factor 1 (EBF1), also referred to as COE1, is a pioneering transcription factor that is crucial for defining B cell lineage. In hematopoiesis, EBF1 promotes the expression of genes that specify B cell lineage commitment, such as FoxO1, PAX5, and IRF-4, while also repressing the expression of transcription factor genes that promote alternate lineages (1,2). EBF1 has also been reported to play a role in olfactory neuronal cell, adipocyte, and early osteoclast differentiation (3-6). Due to the crucial role of EBF1 in B cell development, mutations in EBF1 can lead to the development of B-cell acute lymphoblastic leukemia (B-ALL) (7,8). EBF1 expression is also suppressed in some solid tumor cancers, including genomic loss in breast cancer and downregulation in pancreatic ductal adenocarcinomas (9,10). Lower expression levels of EBF1 also correlate with lower survival rates in patients with cholangiocarcinoma and colorectal carcinoma (CRC), and induced overexpression of EBF1 in CRC cell lines induces cell cycle arrest and apoptosis in vivo and in vitro (11,12).
- Miyai, T. et al. (2018) Genes Dev 32, 112-126.
- Li, R. et al. (2018) Genes Dev 32, 96-111.
- Tsai, R.Y. and Reed, R.R. (1997) J Neurosci 17, 4159-69.
- Wang, S.S. et al. (2004) Development 131, 1377-88.
- Akerblad, P. et al. (2005) Physiol Genomics 23, 206-16.
- Nieminen-Pihala, V. et al. (2021) Bone 146, 115884.
- Kuiper, R.P. et al. (2007) Leukemia 21, 1258-66.
- Mullighan, C.G. et al. (2007) Nature 446, 758-64.
- Neve, R.M. et al. (2006) Cancer Cell 10, 515-27.
- Jones, S. et al. (2008) Science 321, 1801-6.
- Armartmuntree, N. et al. (2018) Redox Biol 14, 637-644.
- Shen, Z. et al. (2020) Front Oncol 10, 1035.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.